The 4R Oncology® Model facilitates enhanced patient engagement and timely care provision by streamlining delivery of complex interdependent care. Implementation of the 4R Oncology® model in breast and lung cancer clinics has improved patients’ involvement in organizing their care, enabled the development of high-functioning multidisciplinary care teams, and helped to optimize the timing and coordination of sequence of care. In this episode, CANCER BUZZ speaks with Raymond Liu, MD, director of research of Hematology-Oncology in Kaiser Permanente Northern California, director of cancer survivorship in Kaiser Permanente San Francisco, and assistant clinical professor at UCSF, who shares how successful implementation of the 4R Oncology® model empowers patients and clinicians and coheres care teams.   <a style= "mso-comment-reference: JR_1; mso-comment-date: 20240410T1324;"> “</a>When people could see that plan, and they could bring that home with them, and they saw that it was all guideline-based and mapped through in a very, very detailed way, they were empowered to answer their questions, especially for their loved ones, and to really reflect on what was said [in the doctor-patient consultation] at home.” –Raymond Liu, MD   “Care is so complex now; our innovations are really, really going fast but we have not been able to deliver the care in a way that’s understandable sometimes, and so by putting it in a single care plan, the patients really engage with it, and we found that the call volumes came down.” –Raymond Liu, MD   Raymond Liu, MD Director of Research of Hematology-Oncology Kaiser Permanente Northern California Oakland, CA   Director of Cancer Survivorship Kaiser Permanente San Franciso San Franciso, CA   Assistant Clinical Professor University of California San Francisco San Francisco, CA   <a style= "mso-comment-reference: JR_3; mso-comment-date: 20240410T1337;">T</a>his episode was developed in connection with the ACCC program <a href= "https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/care-action-plans-for-people-with-cancer"> Care Action Plans for People with Cancer</a>. ACCC, in partnership with the Center for Business Models in Healthcare, is making 4R Care Sequences® available at no cost to ACCC members. 4R Oncology® is the intellectual property of CBM-HC (Executive Frameworks, Ltd.), but is not a commercial product or service. 4R Care Sequence® templates were developed based on studies sponsored by Genentech, Inc.   Resources: <a href= "https://4roncology.com/">4R Oncology®</a> <a href= "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1542" target="_blank" rel="noopener"> JCO Article Fostering High-Functioning Team</a>  <a href= "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1523" target="_blank" rel="noopener"> JCO Impact of 4R Oncology® Model</a>

<description>&lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; The 4R Oncology® Model facilitates enhanced patient engagement and timely care provision by streamlining delivery of complex interdependent care. Implementation of the 4R Oncology® model in breast and lung cancer clinics has improved patients’ involvement in organizing their care, enabled the development of high-functioning multidisciplinary care teams, and helped to optimize the timing and coordination of sequence of care. In this episode, CANCER BUZZ speaks with Raymond Liu, MD, director of research of Hematology-Oncology in Kaiser Permanente Northern California, director of cancer survivorship in Kaiser Permanente San Francisco, and assistant clinical professor at UCSF, who shares how successful implementation of the 4R Oncology® model empowers patients and clinicians and coheres care teams.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a style= "mso-comment-reference: JR_1; mso-comment-date: 20240410T1324;"&gt;&lt;span style="mso-comment-continuation: 2;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; “&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span style= "mso-comment-continuation: 2;"&gt;&lt;span class= "MsoCommentReference"&gt;&lt;span style= "font-size: 8.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi;"&gt;&lt;!-- [if !supportAnnotations]--&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span class="normaltextrun"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt;When people could see that plan, and they could bring that home with them, and they saw that it was all guideline-based and mapped through in a very, very detailed way, they were empowered to answer their questions, especially for their loved ones, and to really reflect on what was said [in the doctor-patient consultation] at home.” –Raymond Liu, MD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; “Care is so complex now; our innovations are really, really going fast but we have not been able to deliver the care in a way that’s understandable sometimes, and so by putting it in a single care plan, the patients really engage with it, and we found that the call volumes came down.” –Raymond Liu, MD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal" style="line-height: normal;"&gt; &lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;&lt;strong&gt;Raymond Liu, MD&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Director of Research of Hematology-Oncology&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Kaiser Permanente Northern California&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Oakland, CA&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt; &lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Director of Cancer Survivorship&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Kaiser Permanente San Franciso&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;San Franciso, CA&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt; &lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;Assistant Clinical Professor&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;University of California San Francisco&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;San Francisco, CA&lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt; &lt;/p&gt; &lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;&lt;a style= "mso-comment-reference: JR_3; mso-comment-date: 20240410T1337;"&gt;T&lt;/a&gt;&lt;span class="MsoCommentReference"&gt;&lt;span style="font-size: 8.0pt;"&gt;&lt;!-- [if !supportAnnotations]--&gt;&lt;/span&gt;&lt;/span&gt;his episode was developed in connection with the ACCC program &lt;a href= "https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/care-action-plans-for-people-with-cancer"&gt; Care Action Plans for People with Cancer&lt;/a&gt;. ACCC, in partnership with the Center for Business Models in Healthcare, is making 4R Care Sequences&lt;span class="normaltextrun"&gt;&lt;span style= "mso-bidi-font-family: Calibri; color: black; background: white;"&gt;® available at no cost to ACCC members. 4R Oncology® is the intellectual property of CBM-HC (Executive Frameworks, Ltd.), but is not a commercial product or service. 4R Care Sequence® templates were developed based on studies sponsored by Genentech, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal" style="line-height: normal;"&gt; &lt;/p&gt; &lt;p class="MsoNormal" style="line-height: normal;"&gt; &lt;strong&gt;Resources:&lt;/strong&gt;&lt;/p&gt; &lt;p class="paragraph" style="vertical-align: baseline;"&gt;&lt;a href= "https://4roncology.com/"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif;"&gt;4R Oncology&lt;/span&gt;&lt;span style= "mso-bookmark: _Hlk163643614;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; background: white;"&gt;®&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;!-- [if !supportNestedAnchors]--&gt;&lt;!--[endif]--&gt;&lt;/p&gt; &lt;p class="paragraph" style="vertical-align: baseline;"&gt;&lt;a href= "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1542" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #467886;"&gt; JCO Article Fostering High-Functioning Team&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style="vertical-align: baseline;"&gt;&lt;a href= "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1523" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #467886;"&gt; JCO Impact of 4R Oncology® Model&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</description>

The 4R Oncology® Model facilitates enhanced patient engagement and timely care provision by streamlining delivery of complex interdependent care. Implementation of the 4R Oncology® model in breast and lung cancer clinics has improved patients’...

Care Action Plans for People with Cancer

While advancements in oral medicine are improving the treatment landscape for head and neck cancer, routine dental care and preventative oral cancer screenings can help identify head and neck cancers early. In this episode, Alessandro Villa, DDS, PhD, MPH, chief of Oral Medicine, Oral Oncology, and Dentistry at Baptist Health South Florida’s Miami Cancer Institute, emphasizes the proactive role dentists can play in early identification of cancer—as well as the need for equitable access to dental care—and explores how a cross-disciplinary cancer care team and patient education work in tandem to better manage complications from head and neck treatment.   “It is widely known that any patient with a diagnosis of head and neck cancer who is scheduled to receive treatment with chemo and radiation therapy should see a dentist prior to starting cancer therapy. We should make sure that access is available for this patient.” —Alessandro Villa, DDS, PhD, MPH    Alessandro Villa, DDS, PhD, MPH Chief of Oral Medicine, Oral Oncology, and Dentistry Miami Cancer Institute, Baptist Health South Florida Miami, FL   <a style= "mso-comment-reference: JR_1; mso-comment-date: 20240326T0846; mso-comment-done: yes;"> This episode was made in connection with the ACCC education program</a> <a href= "https://www.accc-cancer.org/home/learn/cancer-types/head-neck-cancer/multidisciplinary-approaches-to-head-neck-cancer-care"> Multidisciplinary Approaches to Head & Neck Cancer Care</a> in partnership with Head and Neck Cancer Alliance and the American Society of Radiation Oncology (ASTRO) and with support provided by EMD Serono.      Resources:    <a href= "https://www.accc-cancer.org/home/learn/cancer-types/head-neck-cancer/multidisciplinary-approaches-to-head-neck-cancer-care" target="_blank" rel="noopener"> Multidisciplinary Approaches to Head & Neck Cancer Care</a>    <a href= "https://www.headandneck.org/patient-caregiver-resources/" target= "_blank" rel="noopener"> Head and Neck Patient and Caregiver Resources</a>    <a href= "https://www.accc-cancer.org/home/learn/resource-detail/making-the-case-for-head-neck-cancer-patient-care-navigators-mini-podcast-ep-143" target="_blank" rel="noopener"> Making the Case for Head & Neck Cancer Patient Care Navigators</a>

<description>&lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; While advancements in oral medicine are improving the treatment landscape for head and neck cancer, routine dental care and preventative oral cancer screenings can help identify head and neck cancers early.&lt;/span&gt;&lt;/span&gt; &lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black;"&gt; In this episode, Alessandro Villa, DDS, PhD, MPH, chief of Oral Medicine, Oral Oncology, and Dentistry at Baptist Health South Florida’s Miami Cancer Institute, emphasizes the proactive role dentists can play in early identification of cancer—as well as the need for equitable access to dental care—and explores how a cross-disciplinary cancer care team and patient education work in tandem to better manage complications from head and neck treatment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; “It is widely known that any patient with a diagnosis of head and neck cancer who is scheduled to receive treatment with chemo and radiation therapy should see a dentist prior to starting cancer therapy. We should make sure that access is available for this patient.”&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; —Alessandro Villa, DDS, PhD, MPH&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;   &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Alessandro Villa, DDS, PhD, MPH&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Chief of Oral Medicine, Oral Oncology, and Dentistry&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Miami Cancer Institute, Baptist Health South Florida&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Miami, FL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;a style= "mso-comment-reference: JR_1; mso-comment-date: 20240326T0846; mso-comment-done: yes;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #444444; background: white;"&gt; This episode was made in connection with the ACCC education program&lt;/span&gt;&lt;/span&gt;&lt;/a&gt; &lt;a href= "https://www.accc-cancer.org/home/learn/cancer-types/head-neck-cancer/multidisciplinary-approaches-to-head-neck-cancer-care"&gt; &lt;span style="mso-comment-continuation: 1;"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; background: white;"&gt; Multidisciplinary Approaches to Head &amp; Neck Cancer Care&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt; &lt;span style= "mso-comment-continuation: 1;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #444444; background: white;"&gt; in partnership with Head and Neck Cancer Alliance and the American Society of Radiation Oncology (ASTRO) and with support provided by EMD Serono. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Resources:&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span class="normaltextrun"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/cancer-types/head-neck-cancer/multidisciplinary-approaches-to-head-neck-cancer-care" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Multidisciplinary Approaches to Head &amp; Neck Cancer Care&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.headandneck.org/patient-caregiver-resources/" target= "_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Head and Neck Patient and Caregiver Resources&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/resource-detail/making-the-case-for-head-neck-cancer-patient-care-navigators-mini-podcast-ep-143" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Making the Case for Head &amp; Neck Cancer Patient Care Navigators&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;div style="mso-element: comment-list;"&gt; &lt;/div&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt; &lt;!-- [if !supportAnnotations]--&gt;&lt;!--[endif]--&gt;&lt;/p&gt;</description>

While advancements in oral medicine are improving the treatment landscape for head and neck cancer, routine dental care and preventative oral cancer screenings can help identify head and neck cancers early.  In this episode, Alessandro Villa, DDS,...

Beyond the Brush: Navigating Dental Care in Head & Neck Cancer

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist for bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting.     “I think we’re finding these drugs to be highly effective and having high response rates and also very durable response rates in very refractory patients.”—Aaron Cumpston, PharmD, BCOP “I know that in community practice it can be really difficult, but there is a network of institutions out there that have taken on administering these BiTE therapies and have a lot of experience that can be very helpful for those in community practice.” —Christine Barrett, PharmD, BCOP   Aaron Cumpston, PharmD, BCOP  Pharmacy Clinical Specialist – Hematologic Malignancy, Transplant, and Cellular Therapy WVU Medicine  WVU Cancer Institute - Mary Babb Randolph Cancer Center  Morgantown, WV    Christine Barrett, PharmD, BCOP  Medical Oncology Clinical Pharmacy Specialist  WVU Medicine  WVU Cancer Institute - Mary Babb Randolph Cancer Center  Morgantown, WV    This episode was developed in connection with the ACCC education program <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/bispecific-antibodies-in-solid-tumor"> Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor</a> and is supported by Amgen. Resources: <a href= "https://www.accc-cancer.org/docs/projects/bispecific-antibodies/expanding-access-to-cellular-and-bispecific-therapies.pdf?sfvrsn=5b2df5bf_2" target="_blank" rel="noopener"> Expanding Access to Cellular and Bispecific Therapies – Considerations and Recommendations by ACCC and SITC</a>  <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/bispecific-antibodies-in-solid-tumor" target="_blank" rel="noopener"> Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor</a>  <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/best-practices-bispecific-antibodies" target="_blank" rel="noopener"> Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management</a>

<description>&lt;p class="MsoNoSpacing"&gt;&lt;span style= "font-size: 11.0pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: Calibri; color: black; mso-themecolor: text1;"&gt; Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist for bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community setting. &lt;/span&gt;&lt;span style= "font-size: 11.0pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: Calibri;"&gt;&lt;span style="mso-spacerun: yes;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt; &lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;span style= "font-size: 11.0pt; line-height: 116%;"&gt;“I think we’re finding these drugs to be highly effective and having high response rates and also very durable response rates in very refractory patients.”—Aaron Cumpston, PharmD, BCOP&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;span style= "font-size: 11.0pt; line-height: 116%;"&gt;“I know that in community practice it can be really difficult, but there is a network of institutions out there that have taken on administering these BiTE therapies and have a lot of experience that can be very helpful for those in community practice.” —Christine Barrett, PharmD, BCOP&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Aaron Cumpston, PharmD, BCOP&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Pharmacy Clinical Specialist – Hematologic Malignancy, Transplant, and Cellular Therapy&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; WVU Medicine&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; WVU Cancer Institute - Mary Babb Randolph Cancer Center&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Morgantown, WV&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "text-indent: .5in; vertical-align: baseline; margin: 0in 0in 0in .5in;"&gt; &lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Christine Barrett, PharmD, BCOP&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Medical Oncology Clinical Pharmacy Specialist&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; WVU Medicine&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; WVU Cancer Institute - Mary Babb Randolph Cancer Center&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Morgantown, WV&lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt; &lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;span style= "font-size: 11.0pt; line-height: 116%;"&gt;This episode was developed in connection with the ACCC education program&lt;/span&gt; &lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/bispecific-antibodies-in-solid-tumor"&gt; &lt;span style="font-size: 11.0pt; line-height: 116%;"&gt;Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor&lt;/span&gt;&lt;/a&gt; &lt;span style= "font-size: 11.0pt; line-height: 116%;"&gt;and is supported by Amgen.&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; line-height: 116%;"&gt;Resources:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/docs/projects/bispecific-antibodies/expanding-access-to-cellular-and-bispecific-therapies.pdf?sfvrsn=5b2df5bf_2" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Expanding Access to Cellular and Bispecific Therapies – Considerations and Recommendations by ACCC and SITC&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/bispecific-antibodies-in-solid-tumor" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/best-practices-bispecific-antibodies" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: #0563c1;"&gt; Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</description>

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical...

Navigating the Operational Challenges of Treatment with Bispecific Antibodies

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries.    “There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW   Hilary Gee Goeckner, MSW Director, State and Local Campaigns, Access to Care American Cancer Society Cancer Action Network Washington, D.C. This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences. Resources: <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/12/12/the-cost-of-biomarker-testing-moving-from-support-based-to-sustainable-solutions" target="_blank" rel="noopener"> The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions</a>  <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/11/06/comprehensive-cancer-care-the-role-of-biomarker-testing" target="_blank" rel="noopener"> Comprehensive Cancer Care: The Role of Biomarker Testing</a>  <a href= "https://www.accc-cancer.org/podcast/podcast-detail/noc-preview-biomarker-testing-for-medicaid-beneficiaries---mini-podcast" target="_blank" rel="noopener"> Biomarker Testing for Medicaid Beneficiaries (Podcast)</a>  <a href= "https://www.fightcancer.org/what-we-do/access-biomarker-testing" target="_blank" rel="noopener"> Access to Biomarker Testing - American Cancer Society Cancer Action Network</a>   <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/08/31/the-road-to-comprehensive-biomarker-access-for-all" target="_blank" rel="noopener"> The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog</a>  <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/cancer-diagnostics/biomarkers/improving-access-to-biomarker-testing-in-medicaid-populations" target="_blank" rel="noopener"> Improving Access to Biomarker Testing in Medicaid Populations</a>  <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/09/12/precision-medicine-in-rural-and-underserved-areas-unique-solutions-for-unique-challenges" target="_blank" rel="noopener"> Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog</a>  <a href= "https://www.accc-cancer.org/docs/documents/oncology-issues/articles/2022/v37-n1/v37n1-patient-perceptions-of-biomarker-testing.pdf?sfvrsn=e1ef291d_13" target="_blank" rel="noopener"> Patient Perceptions of Biomarker Testing – Oncology Issues</a>  <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/cancer-diagnostics/biomarkers/emerging-biomarkers-innovative-therapies-for-ntrk-gene-fusion-testing" target="_blank" rel="noopener"> Cancer Diagnostics - Biomarkers</a>  <a href= "https://www.accc-cancer.org/home/learn/precision-medicine/care-coordination/eleminating-precision-medicine-disparities" target="_blank" rel="noopener"> Eliminating Precision Medicine Disparities</a>

<description>&lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries. &lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri; color: black; background: white;"&gt; “There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt;  &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Hilary Gee Goeckner, MSW&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; Director, State and Local Campaigns, Access to Care&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Calibri;"&gt; American Cancer Society Cancer Action Network&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;"&gt; Washington, D.C.&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style="vertical-align: baseline;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;"&gt; This episode was developed in connection with the ACCC education program &lt;strong&gt;Improving Access to Biomarker Testing in Medicaid Populations&lt;/strong&gt; and is made&lt;/span&gt; &lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;"&gt; possible with support by Foundation Medicine and Exact Sciences.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; text-indent: -2.25pt; vertical-align: baseline;"&gt; &lt;strong&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin;"&gt; Resources:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/12/12/the-cost-of-biomarker-testing-moving-from-support-based-to-sustainable-solutions" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/11/06/comprehensive-cancer-care-the-role-of-biomarker-testing" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Comprehensive Cancer Care: The Role of Biomarker Testing&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/podcast/podcast-detail/noc-preview-biomarker-testing-for-medicaid-beneficiaries---mini-podcast" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Biomarker Testing for Medicaid Beneficiaries (Podcast)&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.fightcancer.org/what-we-do/access-biomarker-testing" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Access to Biomarker Testing - American Cancer Society Cancer Action Network&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/08/31/the-road-to-comprehensive-biomarker-access-for-all" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/cancer-diagnostics/biomarkers/improving-access-to-biomarker-testing-in-medicaid-populations" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Improving Access to Biomarker Testing in Medicaid Populations&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/09/12/precision-medicine-in-rural-and-underserved-areas-unique-solutions-for-unique-challenges" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/docs/documents/oncology-issues/articles/2022/v37-n1/v37n1-patient-perceptions-of-biomarker-testing.pdf?sfvrsn=e1ef291d_13" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Patient Perceptions of Biomarker Testing – Oncology Issues&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class="eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/cancer-diagnostics/biomarkers/emerging-biomarkers-innovative-therapies-for-ntrk-gene-fusion-testing" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Cancer Diagnostics - Biomarkers&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/precision-medicine/care-coordination/eleminating-precision-medicine-disparities" target="_blank" rel="noopener"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; color: #0563c1;"&gt; Eliminating Precision Medicine Disparities&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "vertical-align: baseline; margin: 0in 0in 0in .75in;"&gt;&lt;span class= "eop"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast;"&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</description>

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER...

Policy Perspectives on Biomarker Testing Coverage for 2024

The ACCC Oncology Reimbursement Meetings (ORMs) help all members of the multidisciplinary cancer care team navigate the annual changes in oncology reimbursement and regulations— while improving their knowledge on effective strategies for success in an everchanging oncology landscape. In this episode, CANCER BUZZ speaks with Jordan Karwedsky, financial counselor, Green Bay Oncology, about her session at the ORMs last fall, where she discussed best practices cancer care teams can adopt as they prepare for the open enrollment season.   “If you have a patient who is uninsured or underinsured, make a note that is a reminder for you so come November when open enrollment begins, you can reach out to them and help them optimize their insurance. In the meantime, if they need treatment, then work with the drug companies to save them as much money on their treatment.”   “Highlights from recent ORMs include how to work with your legislature, either at the state or federal level, to advocate for laws that will help patients.”   Jordan Karwedsky Financial Counselor    Green Bay Oncology     In one of the upcoming ORMs this spring, Karwedsky will share strategies for patient navigation in the digital age. For more information, please visit the <a href= "https://www.accc-cancer.org/home/attend/oncology-reimbursement-meetings"> ACCC website</a>. Resources: ·      <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2021/10/25/preparing-for-open-enrollment">Preparing for Open Enrollment</a> ·      <a href= "https://www.accc-cancer.org/home/learn/financial-advocacy">ACCC Financial Advocacy Network</a> ·      <a href= "https://www.accc-cancer.org/home/learn/financial-advocacy/boot-camp">ACCC Financial Advocacy Boot Camp</a> ·      <a href= "https://www.accc-cancer.org/home/learn/financial-advocacy/patient-assistance-guide">ACCC Patient Assistance & Reimbursement Guide</a> ·      <a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/01/11/patient-navigation-taking-stock-of-the-past-and-looking-to-the-future">Patient Navigation: Taking Stock of the Past and Looking to the Future</a>

<description>&lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;The ACCC Oncology Reimbursement Meetings (ORMs) help all members of the multidisciplinary cancer care team navigate the annual changes in oncology reimbursement and regulations— while improving their knowledge on effective strategies for success in an everchanging oncology landscape. In this episode, CANCER BUZZ speaks with Jordan Karwedsky, financial counselor, Green Bay Oncology, about her session at the ORMs last fall, where she discussed best practices cancer care teams can adopt as they prepare for the open enrollment season.&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;“If you have a patient who is uninsured or underinsured, make a note that is a reminder for you so come November when open enrollment begins, you can reach out to them and help them optimize their insurance. In the meantime, if they need treatment, then work with the drug companies to save them as much money on their treatment.”&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;“Highlights from recent ORMs include how to work with your legislature, either at the state or federal level, to advocate for laws that will help patients.”&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt; &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;strong&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;Jordan Karwedsky&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;Financial Counselor  &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span class= "normaltextrun"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt;Green Bay Oncology &lt;/span&gt;&lt;/span&gt;&lt;span class="eop"&gt;&lt;span style= "font-family: 'Calibri',sans-serif;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p class="paragraph" style= "margin: 0in; vertical-align: baseline;"&gt;&lt;span style= "font-size: 11.0pt; font-family: 'Segoe UI',sans-serif;"&gt; &lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%;"&gt;In one of the upcoming ORMs this spring, Karwedsky will share strategies for patient navigation in the digital age. For more information, please visit the&lt;/span&gt; &lt;a href= "https://www.accc-cancer.org/home/attend/oncology-reimbursement-meetings"&gt; &lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;ACCC website&lt;/span&gt;&lt;/a&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p class="MsoNormal"&gt;&lt;strong&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%;"&gt;Resources:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;     &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2021/10/25/preparing-for-open-enrollment"&gt;&lt;strong&gt;&lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;Preparing for Open Enrollment&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;     &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/financial-advocacy"&gt;&lt;strong&gt;&lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;ACCC Financial Advocacy Network&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;     &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/financial-advocacy/boot-camp"&gt;&lt;strong&gt;&lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;ACCC Financial Advocacy Boot Camp&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;     &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.accc-cancer.org/home/learn/financial-advocacy/patient-assistance-guide"&gt;&lt;strong&gt;&lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;ACCC Patient Assistance &amp; Reimbursement Guide&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt; &lt;p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; mso-list: l0 level1 lfo1;"&gt; &lt;!-- [if !supportLists]--&gt;&lt;span style= "font-size: 12.0pt; line-height: 107%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;"&gt;&lt;span style="mso-list: Ignore;"&gt;·&lt;span style="font: 7.0pt 'Times New Roman';"&gt;     &lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;!--[endif]--&gt;&lt;a href= "https://www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2023/01/11/patient-navigation-taking-stock-of-the-past-and-looking-to-the-future"&gt;&lt;strong&gt;&lt;span style="font-size: 12.0pt; line-height: 107%;"&gt;Patient Navigation: Taking Stock of the Past and Looking to the Future&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;</description>

The ACCC Oncology Reimbursement Meetings (ORMs) help all members of the multidisciplinary cancer care team navigate the annual changes in oncology reimbursement and regulations— while improving their knowledge on effective strategies for success in...

Open Enrollment: Best Practices for End-of-Year Prep

CANCER BUZZ features fresh perspectives on hot topics in oncology care delivery. 

CANCER BUZZ is where stakeholders from the front lines of care to the C-suite, from research to the registry, from chairside to benchside, talk about top-of-mind questions and real-world impact.

CANCER BUZZ

Details

Recent Episodes